Eli Lilly chases $100bn weight loss drug market with $5.3bn US investment
Eli Lilly is investing a further $5.3bn in a new Indiana manufacturing site, one of the biggest investments of its kind, to boost production of its hugely popular diabetes and weight loss drugs, the company said on Friday.
The announcement brings the US drugmaker’s total investment in the site, which is under construction near its Indianapolis headquarters, to $9bn as it races to increase production of the active pharmaceutical ingredients (APIs) behind Mounjaro and Zepbound. The company’s diabetes and weight loss injector pens are currently facing shortages due to soaring demand.


